The presence of the IDH mutation is associated with a significantly better prognosis compared to IDH–wild-type gliomas, and its identification is, therefore, very important for the classification of cerebral gliomas and for clinical therapeutic management. The gene discussed is IDH1; the disease is central nervous system cancer.